1H), 6.60 (s, 1H), 5.75 (s, 1H), 3.66 (t, J = 6.7 Hz, 2H), 3.30-3.11 (m, 2H), 1.65 (s, 6H), 1.55-1.16 (m, 22H), 1.01-0.76 (m, 9H). 13 C-NMR (DMSO-d6) δ 141.4, 138.3, 135.1, 134.4, 133.6, 132.6, 131.6, 130.8, 130.7, 129.0, 128.3, 127.1, 125.3, 122.8, 121.2, 65.4, 56.5, 53.6, 51.9, 31.3, 29.1, 29.0, 28.8, 28.7, 25.5, 24.7, 22.1, 19.4, 13.9, 13.5. HRMS (m/z) Hz, 1H), 7.38 (d, J = 1.7 Hz, 1H), 6.61 (d, J = 3.7 Hz, 1H), 5.73 (s, 1H), 3.99-3.77 (m, 4H), 3.61 (dd, J = 11.5, 3.6 Hz, 1H), 3.30-3.10 (m, 4H), 2.99-2.71 (m, 2H), 1.65 (d, J = 6.8 Hz, 4H), 1.49 (s, 2H), 1.42-1.15 (m, 20H), 1.03-0.73 (m, 18H). 13 C-NMR (DMSO-d6) δ 171. 0, 168.3, 141.4, 138.3, 135.1, 134.4, 133.6, 133.5, 132.6, 131.6, 130.8, 130.7, 129.0, 128.3, 127.1, 125.3, 122.8, 121.2, 66.1(2C), 66.0, 61.4, 3 56.5, 53.6, 51.9, 38.1, 34.1, 29.7, 29.6, 28.3, 23.2, 23.0, 22.4 (2C), 19.4, 13.9 (3C), 13.5, 10.8(3C) Figure S20 . Apparent supersaturation ratio/in vivo correlation plot, displaying the AUC of the apparent supersaturation ratio across the in vitro experiment, and the AUC for in vivo exposure. Data are expressed as mean ± SEM for in vivo AUC (n = 4).
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